Register to our latest webinar here: [ Ссылка ]

The response evaluation of cancer immunotherapy requires differentiation from traditional chemotherapy; hence, it needs more precise criteria that are compatible with the observed response patterns and the well-documented mechanism of action of these novel treatments. This 30 minutes presentation + 15 minutes Q&A provides a review of the latest advances of imaging assessment for cancer immunotherapy evaluation in clinical trials and presents some challenging cases and pitfalls in image interpretation in immunooncology trials.

Presenters:
Dr. Yan Liu, CMO, Median Technologies, Dr. Antoine Iannessi, Medical Director iCRO, Median Technologies - Webinar introduction: Nicolas Dano, COO iCRO, Median Technologies

свернуть